This proprietary state-of-the-art platform provides biotechnology and pharmaceutical companies with the capability to examine how their therapeutic compounds interact with human immune cells in an ex vivo environment. Leveraging advanced computational safety analysis, we ensure a precise evaluation of these interactions. To achieve a comprehensive and diversified understanding of the immune response to various treatments, we utilize a cohort of seven donors.

The data collected from these immune profiles is analysed using AUDACY, our bioinformatics-based analytics solution. The goal of this analysis is to derive significant insights regarding potential clinical outcomes. AUDACY pinpoints active biologically pathways triggered at the injection site that show statistical significance when we administer a compound to our ex vivo skin models.

The ImmunoSafe: ISR Platform^® uses models from 7 donors with 3 replicates to ensure statistically significant results of cytokine expression. This allows for more accurate characterization of the activated biological pathways implicated in the local immune response.

The exponential increase in biological data complexity has reached a point where even highly skilled experts find data analysis incredibly challenging. With this in mind, Genoskin created AUDACY (Automated Data Analysis of Cytokines), a proprietary bioinformatics-based analytical solution.

• Manage large datasets and provide results quickly,
• Minimize the introduction of human error into the analysis,
• Enable novel forms of analysis.

Based on the list of cytokines and chemokines derived from the statistical analysis, AUDACY uses the Protein Interaction Network (PIN) databases to understand their interconnections. The second step entails examining biological pathway databases (such as Reactome) to gain insights into the specific mechanisms that have been activated. Ultimately, the data enable the inference of clinically-related manifestations.